Nov 19 2024 67 mins 1
BioHarvest Sciences CEO Ilan Sobel and Chief Medical Officer Dr. Brian Cornblatt join the show to talk about how BioHarvest Sciences has hacked all of the sustainability and logistical issues that traditionally come with manufacturing plant-based compounds. They discuss the groundbreaking process by which - through its patented technology – BioHarvest Sciences is able to essentially supercharge the compound within the plant that has the most scientifically-backed therapeutic efficacy, all without chemically altering the molecule.
BioHarvest Sciences has figured out how to properly get those healing compounds into the blood stream, into our cells, and into our tissues in an ingenious way - again, without chemically altering the molecule AT ALL. Most importantly, they put enormous amounts of resources into research and development so that their claims are not just theoretical but actually backed by clinical data. Plus, they join the show on an exciting day as BioHarvest Sciences began trading on the NASDAQ.
2:57 – Ilan Sobel’s story and the ethos of BioHarvest Sciences
10:18 – BioHarvest’s patented technology, and how it leverages the most therapeutically efficacious part of the plant and maximizes solubility in a way no other company is able to
21:25 – VINIA’s capacity to potentiate the ability of other supplements to enter the cells through increased blood flow
25:25 – VINIA’s achievement of 82% solubility (proven through clinical data) vs. the 1% solubility of ALL other brands
26:35 – Twelve hours of sustained levels with two peaks (proven by blood testing) vs. twenty minutes for ALL other brands
28:50 – Breaking down the math of how much of piceid resveratrol actually reaches the blood stream as compared to cis and trans (generic) resveratrol
34:20 – The exquisite pharmacokinetics (how a compound gets absorbed and broken down) of VINIA, and the science behind how BioHarvest was able to achieve what no other company has
38:31 – Future plans for BioHarvest to create more products and compounds using their patented technology
41:00 – BioHarvest’s leveraging of the powerful verbascoside molecule for therapeutic purposes within the olive that no one has been able to achieve yet
43:00 – CEO Ilan Sobel reveals BioHarvest’s future plans to partner with nutraceutical, pharmaceutical and cosmetic companies
47:46 – There are 140 drugs that use botanically-based active pharmaceutical ingredients (API). This comes with challenges similar to those of nutraceuticals. BioHarvest’s plans to solve this problem with their patented technology
54:32 – Timeline to produce a product from start to finish (including the research and development). Cost for a company to have BioHarvest create a product, which includes owning the patent
57:43 – Cellular detox and VINIA’s role
59:50 - Dr. Cornblatt breaks down how unique and groundbreaking the soon-to-be-released olive-based product will be
1:03 - CEO Ilan Sobel makes his first public announcement about
BioHarvest Sciences’ debut on the NASDAQ (ticker: BHST)
